Pericytes Modulate Third-Generation Tyrosine Kinase Inhibitor Sensitivity in EGFR-Mutated Lung Cancer Cells Through...

Area of Science:

• Oncology
• Cell Biology
• Molecular Medicine

Background:

• EGFR-mutated lung cancer patients exhibit limited responses to third-generation TKIs.
• Stromal cells, particularly pericytes, may influence TKI resistance.
• Pericytes' role in TKI sensitivity is not fully understood.

Purpose of the Study:

• Investigate the impact of pericytes on TKI response in EGFR-mutated lung cancer.
• Elucidate the molecular mechanisms underlying pericyte-mediated TKI resistance.
• Identify potential therapeutic targets to overcome TKI resistance.

Main Methods:

• Isolation and characterization of pericytes from EGFR-mutated patients.
• Analysis of pericyte secretome and signaling pathways.
• Co-culture experiments with cancer cells and pericytes.
• Single-cell RNA sequencing and multiplex immunostaining of tumor tissues.
• In vivo animal studies.

Main Results:

• Pericytes from EGFR-mutated patients secrete IL32, altering TKI sensitivity.
• IL32-expressing pericytes interact with β5-integrin-expressing cancer cells, impacting prognosis.
• Pericyte-derived IL32 reduces TKI effectiveness by activating the β5-integrin-Src-Akt pathway.
• Silencing IL32 or inhibiting β5-integrin restores TKI sensitivity.
• Pericyte-cancer cell crosstalk, independent of vasculature, affects TKI response.

Conclusions:

• Direct paracrine signaling between pericytes and cancer cells via IL32-β5-integrin mediates TKI resistance.
• Targeting the IL32-β5-integrin axis offers a potential strategy to enhance TKI therapy in EGFR-mutated lung cancer.
• Understanding stromal-cancer cell interactions is crucial for improving lung cancer treatment outcomes.